Search clinical trials for: Tedizolid (BAY119-2631)

Total 392 results

Bayer
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Bacterial Infections

China, United States, Philippines, Taiwan
Trius Therapeutics LLC

Completed

A Phase 1, Open-Label, 10 Day Safety Study

Healthy Subjects

United States
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Gram-Positive Infections

United States, Bulgaria, Colombia, Norway, United Kingdom
University of Southern California
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

Cystic Fibrosis

United States
Amit.Pai
Merck Sharp & Dohme LLC

Completed

Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

Obesity
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
Lundquist Institute for Biomedical Innovation at...

Completed

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

Bone and Joint Infection

United States
Bayer

Terminated

Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study (DART)

Skin Disease, Infectious

Russian Federation, Mexico, Singapore
Bayer

Completed

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Skin Diseases, Infectious

Japan
Trius Therapeutics LLC

Completed

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Healthy Subjects

United States
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Acute Bacterial Skin and Skin Structure Infections

United States, Brazil, Bulgaria, Georgia, Germany, Guatemala, Latvia, Lithuania, Mexico, Poland, Russian Federation, South Africa, Turkey, Ukraine
Trius Therapeutics LLC

Completed

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (ABSSSI)

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Brazil, Canada, Czechia, Germany, Hungary, Latvia, Peru, Slovakia, Ukraine
Hospices Civils de Lyon

Completed

Tedizolid Suppressive Antimicrobial Therapy in a Reference Center (TediSAT)

Bone and Joint Infection

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) (TEDITUB)

Tuberculosis | Multidrug Resistant Tuberculosis

France
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Cubist Pharmaceuticals LLC

Completed

Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Pneumonia
Trius Therapeutics LLC

Completed

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

Healthy Volunteers

United States
Bayer

Terminated

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, Canada, Switzerland, Estonia, Taiwan, France, Chile, Netherlands, United Kingdom, Austria, New Zealand, South Africa, Romania, Croatia, Israel, Germany, Poland, Australia, Denmark, Turkey, Argentina, Lithuan... and more
Trius Therapeutics LLC

Completed

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Bacterial Infection

United States
Trius Therapeutics LLC
Bayer

Completed

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Cellulitis | Erysipelas | Major Cutaneous Abscess

United States
Bayer

Completed

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A (Leopold I)

Hemophilia A | Blood Coagulation Disorders

Spain, Taiwan, Austria, United States, Germany, Thailand, United Kingdom, Italy, Turkey, Croatia, Serbia, Poland, Israel, Sweden, Indonesia, Argentina, Norway, South Africa, India, Hong Kong, Denmark, Pakistan
Trius Therapeutics LLC

Completed

Food Effects of Single Oral Dose of 600mg TR-701

Healthy

United States
Trius Therapeutics LLC

Completed

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Bacterial Infection
Hartford Hospital
Merck Sharp & Dohme LLC

Completed

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Diabetes | Healthy Volunteers | Wound Infection

United States
Trius Therapeutics LLC

Completed

A PK and Safety Study in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal (PROTEDI)

Prostheses Infection
Dong-A ST Co., Ltd.

Completed

Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers

Healthy

Korea, Republic of
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Kolon Life Science

Enrolling by invitation

A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study

Lumbosacral Radiculopathy

United States
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Trius Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) (IV/SAD/MAD)

Bacterial Infections

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

Skin Diseases, Bacterial
Kezar Life Sciences, Inc.

Recruiting

KZR-261 in Subjects With Advanced Solid Malignancies

Advanced/Metastatic Solid Tumor

United States
Trius Therapeutics LLC

Completed

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

Healthy

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria
Trius Therapeutics LLC

Completed

Microdialysis and Pharmacokinetic Study of TR-701

Healthy

United States
Cerevel Therapeutics, LLC

Completed

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

Schizophrenia | Blood Pressure

United States
Trius Therapeutics LLC

Completed

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Skin Diseases, Infectious | Skin Diseases, Bacterial

United States
Bayer

Completed

Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (Phoenix II)

Dermatitis, Atopic

Germany
Trius Therapeutics LLC

Completed

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Healthy Volunteer

United States
Cerevel Therapeutics, LLC

Completed

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Schizophrenia

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Uterine Serous Carcinoma

United States, Australia, Canada, Georgia
Blueprint Medicines Corporation

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis | Monoclonal Mast Cell Activation Syndrome

United States, Spain, Australia, France, Netherlands, Switzerland, Norway, United Kingdom, Austria, Belgium, Germany, Italy, Portugal
Gilead Sciences

Completed

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Akeso

Completed

Study of AK119 in Subjects With Advanced Solid Tumors

Solid Tumor

China
Cerevel Therapeutics, LLC

Completed

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

Schizophrenia

United States
Addpharma Inc.

Completed

A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131

Gastroesophagus Reflux Disease

Korea, Republic of
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia

Search clinical trials for: Tedizolid (BAY119-2631)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations